Ultimovacs (OB:ULTI) - Share price, News & Analysis

ULTI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ULTI Stock Overview

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers.

Rewards

Earnings are forecast to grow 26.46% per year

Risk Analysis

Makes less than USD$1m in revenue (NOK0)

Shareholders have been diluted in the past year

Ultimovacs Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ultimovacs
Historical stock prices
Current Share Price	kr76.40
52 Week High	kr170.20
52 Week Low	kr63.20
Beta	1.27
1 Month Change	-9.05%
3 Month Change	-17.58%
1 Year Change	6.85%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	146.45%

Recent News & Updates

May 19

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

	ULTI	NO Biotechs	NO Market
7D	11.5%	0.7%	3.5%
1Y	6.9%	-47.0%	16.1%

Return vs Industry: ULTI exceeded the Norwegian Biotechs industry which returned -50.5% over the past year.

Return vs Market: ULTI underperformed the Norwegian Market which returned 11.9% over the past year.

Price Volatility

Is ULTI's price volatile compared to industry and market?
ULTI volatility
ULTI Average Weekly Movement	8.1%
Biotechs Industry Average Movement	8.6%
Market Average Movement	7.5%
10% most volatile stocks in NO Market	12.6%
10% least volatile stocks in NO Market	4.3%

Stable Share Price: ULTI is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ULTI's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	24	Carlos de Sousa	https://ultimovacs.com

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Ultimovacs Fundamentals Summary

How do Ultimovacs's earnings and revenue compare to its market cap?
ULTI fundamental statistics
Market Cap	kr2.61b
Earnings (TTM)	-kr164.72m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-15.9x

P/E Ratio

Is ULTI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ULTI income statement (TTM)
Revenue	kr0
Cost of Revenue	kr0
Gross Profit	kr0
Other Expenses	kr164.72m
Earnings	-kr164.72m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Aug 19, 2022

Earnings per share (EPS)	-4.81
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ULTI perform over the long term?

See historical performance and comparison

Valuation

Is Ultimovacs undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.41x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ULTI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ULTI's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ULTI is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ULTI is unprofitable, so we can't compare its PE Ratio to the Norwegian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ULTI's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ULTI is overvalued based on its PB Ratio (4.4x) compared to the NO Biotechs industry average (4x).

Future Growth

How is Ultimovacs forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

26.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ULTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).

Earnings vs Market: ULTI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ULTI's is expected to become profitable in the next 3 years.

Revenue vs Market: ULTI is forecast to have no revenue next year.

High Growth Revenue: ULTI is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ULTI is forecast to be unprofitable in 3 years.

Past Performance

How has Ultimovacs performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-35.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ULTI is currently unprofitable.

Growing Profit Margin: ULTI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ULTI is unprofitable, and losses have increased over the past 5 years at a rate of 35.5% per year.

Accelerating Growth: Unable to compare ULTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ULTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: ULTI has a negative Return on Equity (-27.77%), as it is currently unprofitable.

Financial Health

How is Ultimovacs's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ULTI's short term assets (NOK582.3M) exceed its short term liabilities (NOK50.9M).

Long Term Liabilities: ULTI's short term assets (NOK582.3M) exceed its long term liabilities (NOK11.5M).

Debt to Equity History and Analysis

Debt Level: ULTI is debt free.

Reducing Debt: ULTI had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ULTI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ULTI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30.7% each year

Dividend

What is Ultimovacs's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ULTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ULTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ULTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ULTI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ULTI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure

CEO

Carlos de Sousa (63 yo)

1.92yrs

Tenure

Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...

CEO Compensation Analysis

Compensation vs Market: Carlos's total compensation ($USD5.44M) is above average for companies of similar size in the Norwegian market ($USD493.99K).

Compensation vs Earnings: Insufficient data to compare Carlos's compensation with company performance.

Leadership Team

Experienced Management: ULTI's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: ULTI's board of directors are considered experienced (5.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31